coronavirus
rais
seriou
concern
emerg
zoonot
virus
without
specif
antivir
drug
avail
screen
collect
divers
compound
antihuman
coronaviru
activ
identifi
inhibitor
design
specif
target
membranebound
coronavir
rna
synthesi
exert
potent
antivir
activ
viru
entri
earli
step
viral
life
cycl
specif
format
doubl
membran
vesicl
dmv
hallmark
coronaviru
replic
greatli
impair
upon
treatment
accompani
nearcomplet
inhibit
viral
rna
synthesi
virus
contain
substitut
nonstructur
protein
membranespan
integr
compon
viral
replic
complex
implic
dmv
format
corrobor
target
membran
bound
viral
rna
synthesi
besid
resist
mutant
induc
reduc
number
dmv
display
decreas
specif
infect
rna
synthesi
affect
importantli
inhibit
broad
rang
coronavirus
includ
middl
east
respiratori
syndrom
coronaviru
merscov
effici
inhibit
achiev
primari
human
epithelia
cultur
repres
entri
port
human
coronaviru
infect
collect
studi
propos
evolutionari
conserv
step
life
cycl
positivestrand
rna
virus
recruit
cellular
membran
viral
replic
vulner
importantli
druggabl
target
antivir
intervent
expect
mode
action
serv
paradigm
develop
potent
antivir
drug
combat
mani
anim
human
viru
infect
prior
emerg
highli
pathogen
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
two
circul
human
coronavirus
hcov
caus
rel
mild
common
coldlik
respiratori
tract
infect
known
coronavirus
regard
signific
threat
human
health
ten
year
later
emerg
anoth
highli
pathogen
coronaviru
zoonot
origin
middl
east
respiratori
syndrom
coronaviru
merscov
boost
commun
awar
toward
pend
need
develop
effect
therapeut
option
combat
coronaviru
infect
coronavirus
envelop
virus
posit
strand
rna
genom
largest
rna
virus
encod
mani
nonstructur
protein
nsp
major
structur
protein
accessori
protein
review
mani
protein
provid
essenti
frequent
enzymat
function
viral
life
cycl
therefor
attract
target
antivir
intervent
antivir
strategi
mainli
propos
target
coronaviru
entri
essenti
enzymat
function
coronaviru
proteas
rnadepend
rna
polymeras
rdrp
activ
exampl
spike
protein
mediat
bind
differ
hcov
specif
cellular
receptor
event
associ
preferenti
viru
tropism
either
ciliat
noncili
cell
airway
epithelium
protein
also
mediat
fusion
lipid
viral
envelop
host
cell
plasma
membran
membran
endocyt
vesicl
promot
deliveri
viral
genom
rna
cytoplasm
viru
bind
cell
entri
event
inhibit
antibodi
direct
protein
antibodi
small
molecul
interf
viru
receptor
synthet
peptid
deriv
fusiontrigg
heptad
repeat
region
protein
review
follow
viru
entri
coronaviru
genom
posit
sens
cap
polyadenyl
rna
strand
directli
translat
result
synthesi
coronaviru
replicas
geneencod
nsp
coronaviru
nsp
translat
two
larg
polyprotein
harbor
proteolyt
enzym
name
papainlik
chymotrypsinlik
proteinas
extens
process
coronaviru
polyprotein
liber
nsp
nsp
proteolyt
function
consid
essenti
coronaviru
replic
consequ
number
candid
drug
report
inhibit
coronaviru
polyprotein
process
likewis
coronaviru
rdrp
activ
resid
consid
essenti
coronaviru
replic
attract
target
antivir
intervent
addit
classic
drug
target
coronavirus
encod
array
rnaprocess
enzym
repres
addit
candid
target
includ
helicas
activ
link
ntpase
activ
activ
link
activ
endonucleas
activ
activ
review
like
posit
strand
rna
virus
coronavirus
synthes
viral
rna
organellelik
structur
order
compartment
critic
step
viral
life
cycl
special
environ
enrich
replic
viral
hostcel
factor
time
protect
antivir
host
defens
mechan
grow
bodi
knowledg
concern
involv
rearrang
requir
cellular
membran
rna
synthesi
number
positivestrand
rna
virus
includ
coronavirus
three
coronavir
nsp
ie
thought
particip
format
site
viral
rna
synthesi
particular
protein
contain
multipl
transmembran
domain
thought
anchor
coronaviru
replic
complex
recruit
intracellular
membran
form
reticulovesicular
network
rvn
modifi
frequent
pair
membran
includ
convolut
membran
doubl
membran
vesicl
dvm
interconnect
via
outer
membran
rough
er
inde
angelini
colleagu
recent
shown
coexpress
three
transmembran
domaincontain
sarscov
nsp
requir
induc
dmv
similar
observ
sarscovinfect
cell
organellelik
compart
harbor
membranebound
replic
complex
show
remark
parallel
amongst
broad
rang
positivestrand
rna
viru
famili
potenti
evolutionari
link
similar
mechan
life
cycl
doublestrand
ds
rna
reversetranscrib
cytoplasm
replic
dna
virus
coronaviru
erderiv
dmv
induc
earli
viru
entri
host
cell
cytoplasm
display
strike
similar
dmv
induc
hepat
c
viru
evolutionari
conserv
engag
host
cellderiv
organellelik
membran
structur
viru
rna
synthesi
genet
evid
impair
coronaviru
dmv
integr
associ
sever
reduct
viru
replic
suggest
antivir
intervent
target
membran
involv
viru
replic
repres
attract
howev
yet
larg
unexplor
approach
work
describ
novel
inhibitor
coronaviru
replic
specif
interfer
membranebound
coronavir
rna
synthesi
novel
modeofact
character
sever
impair
dmv
format
result
nearcomplet
inhibit
rna
synthesi
notabl
inhibitor
display
antivir
activ
broad
rang
anim
human
coronavirus
includ
recent
emerg
merscov
identifi
novel
inhibitor
coronaviru
infect
screen
chembionet
collect
compound
antivir
activ
end
cell
grow
plate
supplement
specif
librari
compound
mm
inocul
compound
reduc
abolish
viral
cytopath
effect
retest
plate
format
precis
evalu
antivir
potenti
twostep
screen
procedur
result
sever
hit
includ
two
structur
similar
compound
refer
figur
figur
former
compound
whose
structur
name
z
n
benzamid
examin
detail
compound
complet
solubl
medium
mm
concentr
inhibit
number
plaqu
ic
mm
figur
reduc
viabil
cell
cc
concentr
rang
mm
figur
howev
compound
decreas
prolifer
cell
cc
valu
mm
figur
henc
use
cc
valu
determin
virus
replic
host
cell
cytoplasm
evolv
employ
host
cellderiv
membran
compartment
genom
replic
transcript
specif
positivestrand
rna
virus
accumul
knowledg
concern
involv
rearrang
requir
cellular
membran
rna
synthesi
specifi
establish
viral
replicas
complex
host
cellderiv
membran
evolutionari
conserv
essenti
step
earli
phase
viral
life
cycl
describ
small
compound
inhibitor
coronaviru
replic
specif
target
membranebound
rna
replic
step
ii
broad
antivir
activ
number
divers
coronavirus
includ
highli
pathogen
sarscov
merscov
sinc
resist
mutat
appear
integr
membranespan
compon
coronaviru
replicas
complex
sinc
posit
strand
rna
virus
similar
membranespan
membraneassoci
replicas
compon
implic
anchor
viral
replic
complex
host
cellderiv
membran
data
suggest
membranebound
replic
step
viral
life
cycl
novel
vulner
druggabl
target
antivir
intervent
wide
rang
rna
viru
infect
cell
prolifer
assay
select
index
ie
cc
ic
quotient
compound
although
show
activ
similar
exhibit
somewhat
less
favor
cytotox
profil
cell
viabil
assay
figur
inhibit
earli
post
entri
phase
viral
life
cycl
assess
step
life
cycl
affect
timeofadditionremov
experi
perform
mm
incub
cell
period
two
hour
either
prior
infect
shown
figur
treatment
prior
infect
result
margin
reduct
viru
infect
thu
exclud
blockad
cellular
receptor
modeofact
simultan
addit
viru
result
reduct
viru
infect
suggest
compound
may
interact
viral
particl
thu
inactiv
bind
cellentri
activ
clarifi
possibl
viru
incub
ic
dose
dmso
solvent
min
follow
viru
dilut
titrat
noninhibitori
compound
concentr
similar
titer
observ
viru
treat
dmso
n
two
experi
indic
exhibit
viru
particleinactiv
activ
thu
reduct
plaqu
number
figur
observ
simultan
addit
viru
like
due
cellular
uptak
inhibitori
activ
probabl
yet
metabol
process
compound
earli
step
viru
replic
rather
drug
bind
viral
particl
interfer
penetr
cell
idea
corrobor
pronounc
inhibit
replic
ad
infect
figur
precis
determin
time
window
effici
inhibit
mm
ad
infect
cell
differ
time
point
post
infect
pi
intraand
extracellular
viral
rna
infecti
particl
quantifi
hour
pi
shown
figur
addit
within
first
hour
pi
result
near
complet
inhibit
viral
rna
synthesi
reduct
produc
infecti
viru
suggest
inhibit
potent
post
viru
entri
earli
phase
life
cycl
obtain
insight
concern
target
inhibit
aim
gener
mutant
therefor
subject
plaqu
purifi
consecut
passag
cell
presenc
increas
concentr
mm
two
independ
experi
isol
plaqu
purifi
sever
variant
display
moder
strong
resist
ic
mm
tabl
whole
genom
sequenc
analysi
wild
type
wt
mock
passag
viru
passag
viru
reveal
two
amino
acid
substitut
within
nsp
associ
strong
resist
tabl
sequenc
align
predict
potenti
transmembran
region
homolog
coronavirus
use
studi
reveal
presenc
potenti
membranespan
domain
figur
propos
use
membran
anchor
coronavirus
mutat
confer
resist
locat
near
region
figur
subsequ
gener
recombin
mutant
design
carri
mutat
individu
combin
revers
genet
confirm
mutat
confer
resist
inhibit
reveal
plaqu
inhibit
tabl
timeofaddit
figur
assay
thu
expect
previou
experi
figur
addit
within
first
hour
pi
wt
result
near
complet
inhibit
viral
rna
synthesi
figur
effect
complet
abrog
drugresist
recombin
mutant
virus
figur
notabl
although
amount
intracellular
figur
extracellular
figur
viral
rna
compar
mutant
parent
wt
product
infecti
particl
infect
mutant
virus
greatli
reduc
fold
pi
figur
differ
attribut
presenc
free
viral
rna
prepar
extracellular
viru
sinc
treatment
mutant
viru
ribonucleas
reduc
quantiti
viral
rna
figur
observ
suggest
resistanceconf
mutat
associ
fit
cost
reduc
specif
infect
observ
amino
acid
substitut
confer
resist
strongli
suggest
modeofact
base
interfer
host
cell
membran
requir
coronaviru
replic
express
membranespan
integr
compon
viral
replic
complex
togeth
implic
anchor
coronaviru
replicas
complex
dmv
relat
membran
structur
inde
genet
experiment
evid
concern
alter
coronaviru
dmv
ectop
express
result
format
erderiv
vesicl
therefor
assess
may
impact
format
coronavirusinduc
dmv
electron
microscopi
figur
expect
perinuclear
dmv
cluster
well
viral
particl
readili
detect
wt
cell
figur
sharp
contrast
dmv
cluster
viral
particl
detect
wt
mm
cell
figur
sinc
doublestrand
ds
rna
indic
coronaviru
replic
shown
resid
predominantli
within
inner
lumen
coronavirusinduc
dmv
also
perform
immunofluoresc
analysi
stain
cell
viral
replicas
complex
dsrna
strikingli
characterist
perinuclear
immunofluoresc
stain
pattern
viral
replicas
complex
dsrna
visibl
wt
cell
complet
absent
treatment
figur
confirm
remark
efficaci
inhibit
viral
replic
support
notion
block
format
dmv
contrast
parent
wt
irrespect
whether
appli
recombin
escap
mutant
still
capabl
induc
format
dmv
figur
display
characterist
stain
pattern
replicas
complex
dsrna
figur
likewis
compound
effici
block
replic
figur
dmv
format
wt
resist
recombin
figur
suggest
may
target
modeofact
notabl
cell
infect
escap
mutant
overal
number
dmv
per
cell
reduc
versu
wt
infect
cell
n
similar
previous
describ
mous
hepat
viru
mhv
mutant
number
intracellular
viral
particl
often
pack
tubular
vesiclelik
structur
figur
compar
wt
viru
versu
wt
viru
infect
cell
n
could
also
frequent
detect
dmv
display
partial
collaps
inner
membran
cell
infect
escap
mutant
irrespect
whether
appli
figur
similarli
report
mhv
mutant
suggest
like
pivot
role
coronaviru
dmv
format
overal
find
demonstr
antivir
activ
structur
similar
compound
result
complet
loss
dmv
effici
block
replic
overcom
resist
data
show
target
earli
step
life
cycl
appear
resistanceconf
mutat
suggest
impair
dmv
format
therefor
assess
treatment
may
independ
viru
infect
impact
autophagi
cellular
process
display
similar
coronavir
dmv
format
end
first
transfect
cell
plasmid
encod
order
trace
rapamycininduc
autophagsom
life
imag
analysi
reveal
three
six
hour
ad
rapamycin
cultur
medium
green
fluoresc
autophagocyt
vesicl
becom
appar
irrespect
mm
ad
data
shown
corrobor
result
immunofluoresc
analysi
cell
stain
endogen
six
hour
post
addit
rapamycin
shown
supplementari
figur
rapamycinincuc
autophagocyt
vesicl
readili
detect
presenc
mm
suggest
impact
cellular
autophagi
sinc
inhibit
crucial
step
life
cycl
assess
antivir
activ
panel
divers
coronavirus
repres
major
phylogenet
lineag
band
coronavirus
shown
figur
supplementari
figur
inde
display
antivir
activ
recombin
mhv
strain
express
gaussia
luciferas
marker
viru
replic
recombin
typei
felin
coronaviru
fcov
strain
black
express
renilla
luciferas
marker
viru
replic
avian
infecti
bronchiti
viru
ibv
strain
beaudett
sarscov
strain
suggest
target
broad
rang
coronavirus
furthermor
cytotox
detect
cell
felin
fcwf
cell
murin
cell
primat
vero
cell
origin
concentr
rang
assess
analysi
cytostat
activ
cell
prolifer
assay
reveal
cc
valu
mm
tabl
ie
highest
drug
concentr
use
antivir
assay
notabl
efficaci
inhibit
vari
amongst
differ
coronavirus
howev
whether
relat
function
would
requir
gener
analysi
resist
variant
coronavirus
test
contrast
exhibit
littl
effect
replic
polioviru
figur
pathogen
like
coronavirus
induc
rearrang
cellular
membran
assist
rna
replic
final
assess
efficaci
inhibit
primari
target
cell
respiratori
viru
infect
human
airway
epithelium
fulli
differenti
primari
human
airway
epithelia
hae
cultur
deriv
three
differ
donor
grown
airliquid
interphas
condit
infect
recombin
express
renilla
luciferas
marker
viru
replic
merscov
merscov
first
describ
isol
old
man
acut
pneumonia
renal
failur
fatal
outcom
saudi
arabia
viru
like
zoonot
origin
februari
number
laboratoryconfirm
case
merscov
infect
report
world
health
organ
exceed
includ
case
fatal
outcom
previous
shown
merscov
readili
replic
primari
hae
cell
infect
noncili
cell
express
cellular
receptor
dipeptidyl
peptidas
shown
figur
merscov
infect
inhibit
treatment
remark
efficaci
illustr
reduct
viral
replic
sever
order
magnitud
figur
f
substanti
reduct
dsrna
merscovinfect
primari
hae
cultur
figur
result
demonstr
broad
anticoronavir
activ
make
compound
particularli
promis
develop
efficaci
treatment
option
emerg
coronavirus
merscov
describ
discoveri
novel
class
inhibitor
propos
modeofact
target
membranebound
viral
replic
like
posit
strand
rna
virus
coronavirus
employ
host
cell
membran
assembl
viral
replicas
complex
evolutionari
conserv
strategi
provid
compart
viral
rna
synthesi
enrich
replic
viral
host
cellderiv
protein
believ
protect
antivir
host
cell
defens
mechan
remark
efficaci
inhibit
coronaviru
replic
confirm
employ
host
cell
membran
viral
rna
synthesi
crucial
step
coronaviru
life
cycl
importantli
demonstr
step
extrem
vulner
also
druggabl
antivir
intervent
observ
resist
mediat
mutat
defin
transmembran
domaincontain
nsp
implic
anchor
viral
replicas
complex
host
cellderiv
membran
novel
target
anticoronavir
intervent
moreov
expect
modeofact
serv
paradigm
develop
similar
antivir
drug
combat
infect
caus
mani
posit
strand
rna
virus
notabl
resist
confer
mutat
emerg
consecut
passag
select
far
success
obtain
mutant
data
shown
suggest
escap
mutat
membran
domaincontain
coronaviru
nsp
compat
maintain
effici
rna
synthesi
limit
addit
escap
mutant
obtain
display
remark
reduct
specif
infect
thu
although
rna
synthesi
appear
unaffect
viral
rna
detect
prepar
extracellular
viru
ribonucleas
insensit
impli
adequ
packag
viral
particl
mutat
seem
reduc
viru
fit
thu
conceiv
mutant
may
function
impair
earli
step
viral
life
cycl
sinc
dsrna
local
dmv
escap
mutant
induc
decreas
number
dmv
structur
impair
possibl
reduc
specif
infect
virus
could
relat
dsrnatrigg
innat
immun
respons
sarscov
recent
found
contribut
establish
virusinduc
rvn
promot
vesicl
format
transfect
cell
observ
resist
mutant
gener
decreas
number
dmv
impli
specif
alter
may
advers
affect
vesicleform
capabl
report
mhv
sarscov
predict
hexaspan
protein
compris
conserv
ctermin
cytoplasm
tail
latter
domain
may
serv
wedgelik
amphipath
helix
upon
insert
lipid
membran
trigger
bend
due
induct
posit
membran
curvatur
review
vesicl
format
would
also
requir
put
ion
channel
activ
depolar
curv
membran
thu
facilit
fusion
vesicl
scission
question
whether
compon
coronaviru
replicas
complex
exhibit
activ
would
requir
investig
although
data
reveal
escap
mutat
occur
bind
experi
requir
clarifi
whether
target
directli
observ
activ
inhibit
replic
test
acoronavirus
fcov
ccoronaviru
ibv
wherea
amongst
bcoronavirus
highli
activ
inhibit
merscov
moder
mhv
sarscov
figur
conceiv
may
strong
inhibit
acoronavirus
sinc
identifi
screen
activ
howev
limit
sequenc
similar
coronavirus
figur
allow
predict
strength
inhibit
replic
base
homolog
also
like
address
futur
studi
question
moder
resist
viru
variant
l
contain
mutat
nucleocapsid
escap
inhibit
replic
variant
contrast
contain
resist
mutat
exhibit
moder
resist
consist
select
separ
select
experi
although
nucleocapsid
protein
yet
describ
directli
involv
dmv
format
protein
compon
replicas
complex
may
somehow
affectmodul
function
compensatori
mutat
protein
may
partial
reliev
blockad
altern
possibl
actual
target
may
cellular
protein
process
recruit
cellular
protein
particip
coronavirusinduc
membran
rearrang
interact
could
observ
detect
impact
format
autophagosom
studi
requir
address
may
target
similar
vesicl
edemosom
possibl
compat
observ
phenotyp
dmv
impair
detect
resist
mutat
region
structur
conserv
display
limit
sequenc
similar
thu
conceiv
membran
domaincontain
may
repres
addit
drug
target
similar
describ
relat
arterivirus
coexpress
membranespan
result
membran
alter
dmv
format
similar
observ
arteriviru
infect
coexpress
coronaviru
requir
produc
coronaviruslik
membran
rearrang
includ
dmv
express
alon
combin
two
induc
aberr
membran
rearrang
partial
mimic
membran
structur
known
coronaviru
infect
thu
grow
evid
possibl
er
membraneresid
host
cell
protein
orchestr
critic
event
lead
develop
suitabl
membran
structur
facilit
coronaviru
rna
synthesi
sinc
appar
interfer
process
inhibitor
like
correspond
escap
mutant
like
becom
valuabl
tool
understand
induct
membran
alter
dmv
format
take
place
earli
phase
coronaviru
life
cycl
exampl
coexpress
nativ
mutat
absenc
viru
replic
similar
describ
angelini
colleagu
may
help
clarifi
whether
presenc
would
affect
format
dmv
directli
target
cellular
protein
requir
recruit
dmv
format
emphas
identif
propos
modeofact
first
step
toward
approv
drug
therapeut
use
anim
human
specif
current
focus
structureact
relationship
analysi
analog
aim
identifi
compound
improv
antivir
cytotox
profil
prior
assess
vivo
howev
one
import
lesson
past
sarscov
recent
merscov
outbreak
zoonot
transmiss
coronavirus
human
popul
pose
consider
threat
human
health
warrant
eventu
invest
signific
effort
develop
efficaci
approv
drug
increas
prepared
combat
coronaviru
infect
antivir
activ
number
divers
coronavirus
make
ideal
candid
develop
toward
efficaci
pancoronaviru
inhibitor
broad
anticoronavir
activ
propos
inhibitor
target
highli
conserv
enzymat
function
coronaviru
proteinas
activ
recent
compound
target
host
cell
factor
requir
effici
replic
cyclophilin
concept
target
multipl
key
function
viral
replic
led
develop
efficaci
treatment
regimen
hiv
hepat
c
viru
combin
multipl
antivir
drug
tempt
specul
concept
applic
combat
coronaviru
infect
futur
moreov
identif
demonstr
yet
addit
critic
step
life
cycl
posit
strand
rna
virus
explor
target
antivir
intervent
human
bronchial
epitheli
cell
isol
patient
human
embryon
lung
diploid
fibroblast
african
green
monkey
kidney
cell
vero
babi
hamster
kidney
cell
feli
catu
whole
fetu
cell
purchas
american
type
cultur
collect
atcc
murin
fibroblast
cell
african
green
monkey
kidney
cell
purchas
european
collect
cell
cultur
cell
kind
gift
g
l
smith
imperi
colleg
london
unit
kingdom
african
green
monkey
kidney
gmk
cell
obtain
swedish
institut
infecti
diseas
control
stockholm
cell
grown
eagl
minimum
essenti
medium
emem
gmk
cell
dulbecco
modifi
emem
dmem
vero
cell
supplement
heatinactiv
fetal
calf
serum
hifc
lglutamin
penicillin
mgml
streptomycin
mgml
pest
isol
cultiv
primari
human
bronchial
epitheli
cell
form
pseudostratifieddifferenti
human
airway
epitheli
hae
cultur
perform
describ
previous
human
cov
strain
obtain
atcc
stock
prepar
viru
passag
cell
grow
emem
supplement
hifc
lglutamin
hepe
mm
pest
ememfp
experi
viru
concentr
centrifug
infecti
cultur
fluid
cell
ml
cushion
sucros
h
rpm
rotor
beckman
pellet
cover
pb
mm
nacl
mm
kcl
mm
mm
left
overnight
gentli
suspend
pipet
follow
virus
propag
describ
previous
recombin
recombin
express
renilla
luciferas
recombin
felin
coronaviru
strain
black
express
renilla
luciferas
recfcovrl
sarscov
strain
recombin
avian
infecti
bronchiti
viru
ibv
strain
beaudett
merscov
recombin
mhv
strain
express
gaussia
luciferas
mhvgluc
gener
base
previous
describ
revers
genet
system
briefli
accessori
gene
replac
gene
encod
codonoptim
gaussia
luciferas
hgluc
use
vacciniavirusmedi
homolog
recombin
essenti
describ
gener
plasmid
dna
use
recombin
contain
nucleotid
nt
hgluc
gaussia
luciferas
gene
nt
recombin
contain
mutat
confer
resist
gener
base
previous
describ
revers
genet
system
briefli
vaccinia
viru
contain
fulllength
cdna
use
recombin
plasmid
base
escherichia
coli
result
vaccinia
virus
use
rescu
describ
previous
ident
plasmid
dna
recombin
vaccinia
virus
recombin
coronavirus
confirm
sequenc
experi
polioviru
strain
sabin
obtain
swedish
institut
infecti
diseas
control
stockholm
use
chembionet
divers
librari
compound
obtain
leibniz
institut
molecular
pharmacolog
berlin
germani
librari
provid
well
plate
format
well
contain
ml
compound
solubil
dmso
final
concentr
mm
hit
compound
purchas
chemdiv
san
diego
ca
catalog
number
correct
structur
puriti
confirm
laboratori
nmr
lcm
analys
cell
infect
multipl
infect
moi
recombin
without
presenc
mm
cell
fix
h
pi
paraformaldehyd
pfa
immunostain
use
mous
monoclon
antidsrna
english
scientif
consult
bt
rabbit
kindli
provid
john
ziebuhr
univers
giessen
germani
primari
antibodi
detect
doublestrand
ds
rna
viral
replic
complex
donkey
deriv
dylight
label
antimous
igg
hl
dylight
label
antirabbit
igg
hl
jackson
immunoresearch
appli
secondari
antibodi
cell
counterstain
dapi
invitrogen
visual
nuclei
hae
cell
cultur
inocul
plaqu
form
unit
pfu
without
presenc
mm
fix
pfa
h
pi
stain
perform
mous
monoclon
antibodi
direct
dsrna
goat
polyclon
tight
junction
abcam
primari
antibodi
dylight
donkey
antimous
igg
hl
dylight
donkey
antigoat
igg
hl
jackson
immunoresearch
appli
secondari
antibodi
follow
two
separ
incub
step
alexa
rabbit
monoclon
antibetatubulin
antibodi
ciliat
cell
cell
signal
dapi
invitrogen
imag
acquir
use
ecplan
neofluar
ec
planneofluar
oil
dic
object
zeiss
lsm
confoc
microscop
imag
captur
analysi
process
perform
use
zen
zeiss
imari
bitplan
scientif
softwar
softwar
packag
screen
assay
perform
describ
previous
respiratori
syncyti
viru
briefli
cell
seed
well
plate
costarcorn
ny
usa
becom
confluent
one
day
cultur
growth
medium
remov
cell
supplement
consecut
ml
ememfp
medium
ml
volum
librari
compound
mm
concentr
pfu
ml
ememfp
last
two
column
well
plate
receiv
either
viru
ememfp
medium
serv
control
cell
observ
microscop
protect
virusinduc
cytopath
effect
day
incub
plaqu
reduct
assay
determin
antivir
effect
done
follow
cell
seed
plate
becom
nearli
confluent
one
day
cultur
serial
fivefold
dilut
mm
pfu
viru
ml
ememfp
medium
ad
incub
cell
h
subsequ
viruscompound
mixtur
remov
cell
ml
volum
methylcellulos
mc
solut
ememfp
medium
supplement
concentr
ad
plate
cell
incub
day
stain
solut
crystal
violet
visual
viral
plaqu
h
viral
inoculum
remov
cell
rins
three
time
pb
fresh
medium
contain
concentr
dmso
ad
coronaviru
replic
assess
cell
cultur
supernat
determin
titer
tissu
cultur
infecti
dose
produc
patholog
chang
cell
cultur
inocul
ibv
polioviru
h
pi
determin
amount
viral
genom
rna
produc
qrtpcr
specif
sarscov
merscov
h
pi
describ
previous
determin
level
renilla
express
h
pi
h
pi
recfcovrl
use
renilla
luciferas
assay
system
promega
gaussia
luciferas
express
mhvgluc
h
pi
use
biolux
gaussia
luciferas
assay
kit
neb
respect
virucid
assay
ml
suspens
pfu
ememfp
medium
mix
mm
incub
min
control
sampl
viru
incub
dmso
solvent
final
concentr
correspond
present
test
compound
mixtur
dilut
serial
tenfold
ememfp
medium
residu
viru
infect
determin
viral
plaqu
assay
toxic
solvent
dmso
cell
evalu
use
tetrazoliumbas
celltit
aqueou
one
solut
cytotox
assay
promega
effect
solvent
prolifer
cell
studi
follow
cell
seed
well
plate
becom
confluent
one
day
cultur
growth
medium
remov
cell
incub
specif
concentr
solvent
ememfp
medium
h
cell
dissoci
trypsinedta
solut
count
effect
dmso
viabil
vero
cell
assess
use
cytotoxglo
cytotox
assay
kit
promega
toxic
test
compound
differenti
hae
cultur
evalu
celltiterglo
luminesc
cell
viabil
assay
kit
promega
cell
grow
well
plate
precool
min
room
temperatur
anoth
min
cell
rins
ml
cold
ememfp
inocul
moi
follow
viru
adsorpt
cell
min
cell
rins
twice
ml
cold
ememfp
ml
warm
ememfp
medium
ad
subsequ
ml
mm
ad
specif
time
point
rel
end
viru
adsorpt
period
infecti
cell
cultur
medium
cell
harvest
time
point
h
cell
cultur
supernat
medium
clarifi
centrifug
min
pellet
cell
suspend
rnasefre
water
store
quantif
rtpcr
assay
studi
effect
earli
viruscel
interact
timeofaddit
assay
modifi
follow
cell
rins
ml
ememfp
ml
ememfp
supplement
mm
ad
compound
incub
cell
h
either
prior
h
period
infect
cell
pfu
viru
ml
ememfp
cell
wash
ml
ememfp
h
period
incub
compound
andor
viru
final
cell
overlaid
mc
solut
incub
day
stain
crystal
violet
visual
viral
plaqu
rt
taqman
pcr
carri
describ
brittainlong
et
al
briefli
extract
rna
conduct
magnapur
lc
robot
use
magna
pure
lc
total
nucleic
acid
isol
kit
roch
appli
scienc
mannheim
germani
amplif
perform
use
taqman
real
time
pcr
system
appli
biosystem
foster
citi
ca
pair
forward
revers
primer
well
probe
specif
genom
fragment
code
nucleocapsid
protein
number
rna
copi
determin
relat
detect
cycl
threshold
valu
standard
curv
prepar
base
five
tenfold
dilut
specif
plasmid
compris
bp
insert
nucleocapsid
sequenc
qrtpcr
assay
quantifi
sarscov
merscov
genom
rna
describ
previous
prepar
drugresist
variant
sequenc
analysi
procedur
describ
previous
respiratori
syncyti
viru
use
briefli
plaqu
purifi
subject
consecut
passag
cell
presenc
increas
concentr
mm
control
purpos
viru
also
passag
cell
absenc
inhibitor
viru
subject
two
round
plaqu
purif
presenc
inhibitor
rel
drugresist
test
use
viral
plaqu
reduct
assay
genom
rna
origin
mockpassag
viru
passag
extract
extracellular
fluid
cell
use
qiaamp
viral
rna
purif
kit
qiagen
overlap
dna
fragment
cover
entir
code
sequenc
produc
revers
transcript
pcr
subject
nucleotid
sequenc
use
abi
prism
big
dye
termin
cycl
sequenc
readi
reaction
kit
appli
biosystem
nucleotid
sequenc
analysi
perform
use
sequench
softwar
gene
code
corpor
cell
grow
well
plate
precool
min
room
temperatur
anoth
min
cell
rins
ml
cold
ememfp
inocul
concentr
prepar
see
cell
virus
section
moi
follow
viru
adsorpt
cell
h
cell
rins
thrice
ml
cold
ememfp
ml
warm
ememfp
medium
ad
supernat
fluid
infect
cell
harvest
specif
time
point
rel
end
viru
adsorpt
period
process
determin
viral
rna
infect
describ
timeofaddit
assay
infecti
cultur
medium
compris
recombin
mutant
clarifi
centrifug
min
ml
volum
supernat
supplement
ml
mg
ribonucleas
thermo
fisher
scientif
solvent
sampl
spike
mg
rna
purifi
human
respiratori
syncyti
viru
rsv
serv
intern
control
ribonucleas
activ
follow
incub
virusenzym
mixtur
min
coronavir
rsv
rna
quantifi
rt
taqman
pcr
describ
brittainlong
et
al
coronaviru
infect
determin
plaqu
titrat
assess
timefram
autophagi
vesicl
format
occur
seed
cell
cell
glass
bottom
cluster
plate
mattek
fortyeight
hour
prior
stimul
cell
transfect
plasmid
use
invitrogen
accord
manufactur
protocol
hereaft
cell
expos
nm
rapamycin
invivogen
alon
presenc
either
mm
equal
volum
dmso
durat
hour
fluoresc
differenti
interfer
contrast
dic
imag
acquir
minut
interv
use
ec
plan
neofluar
oil
dic
object
zeiss
lsm
confoc
microscop
imag
captur
analysi
process
perform
use
zen
zeiss
determin
whether
inhibit
endogen
autophagi
vesicl
format
stimul
cell
cell
nm
rapamycin
alon
presenc
either
mm
equal
volum
dmso
durat
six
hour
unstimul
cell
use
mock
control
cell
fix
immunostain
previous
describ
rabbit
polyclon
sigma
aldrich
appli
primari
antibodi
detect
autophagi
vesicl
goat
deriv
label
antirabbit
igg
hl
jackson
immunoresearch
appli
secondari
antibodi
thereaft
cell
counterstain
dapi
invitrogen
fluoresc
imag
acquir
use
plapon
object
olympu
confoc
microscop
imag
captur
analysi
process
perform
use
olympu
fluoview
softwar
cell
grow
melinex
polyest
film
agar
scientif
ltd
stanst
uk
well
cluster
plate
infect
moi
presenc
mm
h
infect
cultur
medium
remov
cell
rins
twice
eagl
medium
fresh
eagl
medium
supplement
glutaraldehyd
ad
incub
min
cell
wash
twice
trishcl
buffer
ph
supplement
mm
process
electron
microscopi
describ
experi
recombin
mutant
virus
origin
viru
carri
similar
manner
except
cell
inocul
moi
incub
without
presenc
mm
